Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Acetaminophen  COVID-19 treatment studies for Acetaminophen  C19 studies: Acetaminophen  Acetaminophen   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Death/hospitalization -15% Improvement Relative Risk Death/hospitalization (b) -29% Death/hospitalization (c) -75% late Lapi et al. Acetaminophen for COVID-19 EARLY TREATMENT Is early treatment with acetaminophen beneficial for COVID-19? Retrospective study in Italy No significant difference in death/hosp. Lapi et al., Internal and Emergency Medicine, doi:10.1007/s11739-022-03054-1 Favors acetaminophen Favors control
To clarify the safety profile of paracetamol for home-care patients with COVID-19: a real-world cohort study, with nested case–control analysis, in primary care
Lapi et al., Internal and Emergency Medicine, doi:10.1007/s11739-022-03054-1
Lapi et al., To clarify the safety profile of paracetamol for home-care patients with COVID-19: a real-world cohort study,.., Internal and Emergency Medicine, doi:10.1007/s11739-022-03054-1
Jul 2022   Source   PDF  
  All Studies   Meta
Retrospective paracetamol use with a primary care database in Italy, showing no significant difference in hospitalization/death for use 0-3 and 4-7 days from diagnosis, and significantly higher risk for use >7 days from diagnosis. Confounding by indication may have a greater effect on late usage.
risk of death/hospitalization, 15.0% higher, OR 1.15, p = 0.22, adjusted per study, early use, RR approximated with OR.
risk of death/hospitalization, 29.0% higher, OR 1.29, p = 0.52, adjusted per study, mid-term use, RR approximated with OR.
risk of death/hospitalization, 75.0% higher, OR 1.75, p < 0.001, adjusted per study, late use, RR approximated with OR, late treatment result, excluded in exclusion analyses: substantial unadjusted confounding by indication likely.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Lapi et al., 30 Jul 2022, retrospective, Italy, peer-reviewed, 8 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAcetaminophenAll
Abstract: Internal and Emergency Medicine IM-ORIGINAL To clarify the safety profile of paracetamol for home‑care patients with COVID‑19: a real‑world cohort study, with nested case–control analysis, in primary care Francesco Lapi1 · Ettore Marconi1 · Ignazio Grattagliano2 · Alessandro Rossi2 · Diego Fornasari3 · Alberto Magni2 · Pierangelo Lora Aprile2 · Claudio Cricelli2 Received: 3 June 2022 / Accepted: 11 July 2022 © The Author(s), under exclusive licence to Società Italiana di Medicina Interna (SIMI) 2022 Abstract Background and objective This study aimed to compare the prescribing patterns of paracetamol in COVID-19 with those for similar respiratory conditions and investigated the association between paracetamol use and COVID-19-related hospitalization/death. Methods Using a primary care data source, we conducted a cohort study to calculate the incidence rate of paracetamol use in COVID-19 and for similar respiratory conditions in 2020 and 2019 (i.e. pre-pandemic phase), respectively. In the study cohort, we nested a case–control analyses to investigate the association between paracetamol use and COVID-19-related hospitalizations/deaths. Results Overall, 1554 (33.4 per 1000) and 2566 patients (78.3 per 1000) were newly prescribed with paracetamol to treat COVID-19 or other respiratory conditions, respectively. Those aged 35–44 showed the highest prevalence rate (44.7 or 99.0 per 1000), while the oldest category reported the lowest value (17.8 or 39.8 per 1000). There was no association for early (OR = 1.15; 95% CI: 0.92–1.43) or mid-term (OR = 1.29; 95% CI: 0.61–2.73) users of paracetamol vs. non-users. Instead, the late users of paracetamol showed a statistically significant increased risk of hospitalization/death (OR = 1.75; 95% CI: 1.4–2.2). Conclusions Our findings provide reassuring evidence on the use and safety profile of paracetamol to treat early symptoms of COVID-19 as in other respiratory infections. Keywords Paracetamol · Prescribing pattern · Safety profile · Home-care · COVID-19 Background The SARS-CoV-2 pandemic is still burdening the healthcare system of several Western countries. Patients with mild-tomoderate COVID-19, for whom home-care treatment is requested, generally present flu-like symptoms such as fever, * Francesco Lapi 1 Health Search, Italian College of General Practitioners and Primary Care, Via del Sansovino 179, 50142 Florence, Italy 2 Italian College of General Practitioners and Primary Care, Florence, Italy 3 Department Medical Biotechnology and Translational Medicine, Università Degli Studi Di Milano, Milan, Italy pharyngitis, cough, rhinitis, headache, and myalgia [1, 2]. Among the available medications, paracetamol is recommended by the World Health Organization (WHO) [3], the National Institute for Health and Care Excellence (NICE) [4] as well as other regulatory agencies [5, 6] and scientific societies [7] among the mainstays to manage coronavirusrelated early symptoms. Nevertheless, there was conflicting and misleading communication [8, 9] on the pharmacotherapy for the home care of COVID-19. Some clinicians and researchers raised concerns on the safety profile of paracetamol when used in SARS-CoV-2 infections [10, 11]. They underlined that the potential depletion of glutathione (GSH) induced by paracetamol may even favour the pulmonary endothelium damages by SARS-CoV-2 [10, 12]. The authors therefore recommended to avoid the..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop